An overview on diagnosis and management approach of systemic Lupus Erythematosus

Doaa Mohammed Mohammed¹, Afnan Abdullah Al Namankany², Eman Mazyad Alruwaili³, Ahmed Abdullah Al Nasi⁴, Jomanah Ahmed Shahbaz⁵, Roaa Salah Alabiri⁶, Ruba Salah Alabiri⁷, Rawan Bader Alanazi⁸, Abdullah Salem Bin Merdah⁹, Haitham Mohammed Bin Hararah¹⁰, Shahad Adel Aljohani¹¹

¹General Practitioner, Ministry of Interior, Jeddah, KSA. ²Department of Medicine, Al Noor Specialist Hospital, Makkah, KSA. ³Faculty of Medicine, Northern Border University, Arar, KSA. ⁴Emergency Department, Safwa General Hospital, Eastern Province, KSA. ⁵Faculty of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, KSA. ⁶Faculty of Medicine, Gulf Medical University, Manama, Bahrain. ⁷Faculty of Medicine, Al Jouf University, Al Jouf, KSA. ⁸Department of Critical Care, King Fahd Hospital, Medina, KSA. ⁹Emergency Department, Aboaresh General Hospital, Jazan, KSA. ¹⁰Faculty of Medicine, Ibn Sina National College, Jeddah, KSA.

Abstract

Background: The systemic lupus erythematosus (SLE) is a chronic prototypical systemic autoimmune disease with extremely varied clinical manifestations, pathogenesis, and epidemiological burden worldwide among different racial, ethnic age, and gender groups. The disease has a complex form of pathogenesis that is not fully understood as SLE has extremely varied clinical manifestations and continues to have unpredictable courses. However, the approach to SLE imposes complex modalities of management and highly experienced clinicians. Initial clinical evaluation and new classification criteria are anticipated for a better diagnostic approach. Objective: To assist internists in understanding Systemic Lupus erythematosus and the constantly evolving diagnostic criteria and recommended modalities of management, as well as observing the major risk factors. Methodology: This review included clinical evidence-based guidelines conducted and analyzed by the PubMed search and only English articles, documents, and evidence-based clinical trials were included. The terms were applied within the title or abstract title ("SLE"[Mesh] AND “Lupus” Mesh] AND “Criteria”[Mesh] AND “Management”[Mesh]). Conclusion: The new criteria structure will prove useful in the diagnosis of questionable SLE patients. Approach to SLE involves complex modalities of treatment and early detection of SLE comorbidities is the cornerstone of management.

Keywords: SLE, Epidemiology, Criteria, Classification, Management

Introduction

The systemic lupus erythematosus (SLE) is a chronic prototypical systemic autoimmune disease with extremely varied clinical manifestations, pathogenesis, and epidemiological burden worldwide among different racial, ethnic age, and gender groups.¹,² The complex etiology and clinical variations of SLE make it a difficult disease to grasp in clinical practice.³ Classification criteria is an essential diagnostic approach for defining SLE unpredictable courses. Furthermore, the approach to SLE elaborates complex modalities of treatment that requires experienced clinicians.⁴ This review will improve the understanding of Systemic Lupus erythematosus for internists and provide the constantly evolving diagnostic criteria and recommended modalities of managing the disease, as well as observing the risk factors and morbidity and mortality rates.

Methodology

This review included clinical evidence-based guidelines conducted and analyzed by the PubMed search and only English articles, documents, and evidence-based clinical trials were included. The terms were applied within the title or abstract title ("SLE"[Mesh] AND “Lupus” Mesh] AND “Criteria”[Mesh] AND “Management”[Mesh]). In regards to the inclusion criteria, the articles were selected based on the inclusion of one of the following topics: systemic lupus erythematosus, approach, evaluation, diagnosis, and management. Exclusion criteria were all other articles that did not have one of these topics as their primary endpoint.

Review Epidemiology

A recent 2018 study had accurately described a worldwide prevalence and incidence of SLE. California Lupus

Address for correspondence: Haitham Mohammed Bin Hararah, Emergency Department, Aboaresh General Hospital, Jazan, KSA. Email: h1m2n3h @ hotmail.com

How to cite this article: Mohammed D M, Alnamankany A A, Alruwaili E M, Al-Nasif A A, Shahbaz J A, Alabiri R S, et al. An overview on diagnosis and management approach of systemic Lupus Erythematosus. Arch. Pharm. Pract. 2021;12(1):41-3. https://doi.org/10.51847/gz8DAMBMnZ
Systemic lupus erythematosus progress and severity depend on the course of the disease and major systemic involvement, including most commonly the skin, renal, musculoskeletal cardiopulmonary, hematologic reproductive, and neuropsychiatric systems. Systemic lupus erythematosus has extremely varied clinical manifestations and continues to have unpredictable courses. Once SLE is suspected initial clinical evaluation and diagnostic criteria (Table 1).

In 2012, ACR (American College of Rheumatology) classification criteria performed better results in terms of sensitivity rather than specificity while SLICC (Systemic Lupus International Collaborating Clinics) classification criteria anticipated better results in terms of specificity. However, in 2017 a new perspective has been revised and presented a jointly supported ACR/EULAR (European League Against Rheumatism) criteria with a percentage of (93-97%) specificity and (96-98%) in terms of sensitivity.

In 2019, EULAR/ACR has been adapted as a new classification criterion. EULAR is built on previous classification criteria adding non-infectious fever as a new item in the early stages of SLE and ANA (antinuclear antibodies) as an essential criterion. Moreover, EULAR introduced a more logical approach to identify SLE with sufficient 10 points; reaching 6 points is significant for maintaining EULAR classification. On the other hand, ACR structure for classification depends on detecting any 4 of the 11 ACR criteria, while SLICC structure depends mainly on histological compatibility with lupus nephritis and abnormal ANA titers of anti-dsDNA or any 4 of the 17 features that must include at least one immunological symptom.

### Diagnosis

**Pathogenesis**

SLE has a complex form of pathogenesis that is not fully understood. According to a 2015 study, genetic factors have an enormous impact on the pathogenicity of SLE and other autoimmune disorders. SLE was estimated with a first-degree relative risk of 5.87% but with high heritability rates of 43.9%. Environmental factors linked to exogenous and indigenous mechanisms also have a potential association with SLE pathogenicity. Several Exogenous factors linked to SLE pathogenicity such as solvents, UV radiation, pesticides. Moreover, intrinsic factors include the patient’s reproductive history in females mostly and latent infections as Epstein Barr virus infection. The effect of these environmental factors leads to activation of the innate immune cells and self-reactive lymphocytes. Drugs induced lupus erythematosus are reported in rare cases.

**Table 1: Diagnosis of SLE in three classifications Involving SLICC, ACR and new EULAR/ACR 2019 Criteria**

| Systems       | SLICC                                      | ACR                                      | EULAR/ACR 2019                          |
|---------------|--------------------------------------------|------------------------------------------|-----------------------------------------|
| Skin          | Subacute or acute cutaneous lupus          | Malar (Butterfly) facial rash            | Acute cutaneous lupus [6]                |
|               | -ANA Positive results, antiphospholipid    | -ANA Positive results                    | Subacute lupus [4]                      |
|               | antibodies or anti-Sm, anti-dsDNA, low     | - Elevated antiphospholipid antibodies   | Discoid lupus [4]                       |
|               | complement (C3, C4, CH50),                | or anti-Sm, anti-dsDNA                   |                                        |
| Immunologic   | direct Coombs test (Hemolytic anemia)      | - Discoid rash                           |                                        |
|               | - Chronic cutaneous lupus                  | - Oral and nasal ulcers                  |                                         |
|               | - Oral and nasal ulcers                   | - Photosensitivity                       |                                         |
|               | - Non-scarring alopecia                   |                                         |                                         |
| Musculoskeletal| Synovitis in 2 or more joints (effusion or| Arthritis in 2 or more joints           | Arthritis [6]                           |
|               | swelling) morning stiffness for 30minutes  |                                          |                                        |
| Renal         | Urinary Creatinine >500mg or red cell     | Persistent proteinuria or red cell cast   | - Proteinuria [4]                        |
|               | casts/24hours                              |                                          | - Lupus nephritis Classes:              |
|               |                                            |                                          | - II/IV [8]                             |
|               |                                            |                                          | - III/IV [10]                           |
Hematologic
Leukopenia <4000 cell/mm³ more than once or lymphopenia <1500cell/mm³ 
Hemolytic anemia, 
Thrombocytopenia< 100,000 cells/mm³

Neuropsychiatric
Mononeuritis complex, psychosis, 
Seizures, cranial or peripheral neuropathy, myelitis

Cardiopulmonary
Serositis (involves pleurisy, pericardial and pleural effusion and pericarditis)

However, detection of SLE does not rely upon fulfilling classification criteria itself, but rather depends on the physician performance and his approach to an SLE patient.\(^1\)

Management
The approach to SLE involves complex modalities of treatment that requires experienced clinicians from different specialties.\(^4\) In general, early detection of SLE comorbidities is the cornerstone of management. SLE comorbidities are highly associated with modifiable life-threatening risks especially in patients with cardiovascular (with a higher prevalence of 28-40%) and renal involvement. About 50% of patients are presented with renal injury (Lupus nephritis) notably in elderly individuals and 15% are presented with homocysteinemia, both are considered risk factors for myocardial infarction and thrombosis in patients with lupus.\(^11,15\)

As an internist, patients with SLE should receive intense educational guidance and support sessions as SLE therapeutic measures are sometimes non-pharmacological. Changing lifestyle activities to avoid future complications is essential. Recommend regular exercise to avoid generalized fatigability and improve cognitive dysfunction that accompanies fibromyalgia. It is recommended to educate patients about cardiovascular and renal complications as well as possible opportunistic infections such as pneumonia. Refer to Rheumatologist for further checkup.\(^11,15\)

Conclusion
The systemic lupus erythematosus (SLE) is a chronic prototypical systemic autoimmune disease with extremely varied clinical manifestations. The new criteria structure will prove useful in the diagnosis of questionable SLE patients. Approach to SLE involves complex modalities of treatment and early detection of SLE comorbidities is the cornerstone of management. The internist needs to coordinate closely with a rheumatologist to improve the quality of care for the SLE patient.

REFERENCES
1. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018;30(2):144-150.
2. Zuccaci D, Elefante E, Calabresi E, Signorini V, Bortoluzzi A, Tani C. One year in review 2019: systemic lupus erythematosus. Clin Exp Rheumatol. 2019;37(5):715-722.
3. Parks CG, de Souza Espindola Santos A, Barbhaiya M, Costenbader KH. Understanding the role of environmental factors in the development of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):306-320.
4. Tunnicliffe DJ, Singh-Grewal D, Kim S, Craig JC, Tong A, Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines. Arthritis Care Res (Hoboken). 2015;67(10):1440-1452.
5. Al Dhanhani AM, Agarwal M, Othman YS, Bakoush O. Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE. Lupus. 2017;26(6):664-669.
6. Kuo CF, Grainge MJ, Valdes AM, See LC, Luo SF, Yu KH, Zhang W, Doherty M. Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoimmune Diseases in Affected Families. JAMA Intern Med. 2015;175(9):1518-1526.
7. Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends Mol Med. 2017;23(7):615-635.
8. La Paglia GM, Leone MC, Lepri G, Vagelli R, Valentini E, Alunno A, Tani C. One year in review 2017: systemic lupus erythematosus. Clin Exp Rheumatol. 2017;35(4):551-561.
9. He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018;30(5):490-497.
10. Vasquez-Canizaros N, Wahezi D, Putterman C. Diagnostic, and prognostic tests in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):351-363.
11. Lam NC, Ghetu MV, Bieniek ML. Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management. Am Fam Physician. 2016;94(4):284-294.
12. Filotozo R, Mandrastrava V. Cutaneous lupus erythematosus: clinicopathologic correlation. G Ital Dermatol Venereol. 2018;153(2):216-229.
13. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Bournpas DT, Kamen DL, Jayne D. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159.
14. Aringer M, Leuchten N, Johnson SR. New Criteria for Lupus. Curr Rheumatol Rep. 2020;22(6):18.
15. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2019;96:1-13.